Workflow
Brainstorm Cell Therapeutics(BCLI)
icon
Search documents
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Prnewswire· 2024-04-10 10:00
NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo.Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS. NEW YORK, April 10, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve. The ...
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Prnewswire· 2024-04-09 10:00
Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).  The SPA agreement with the FDA validates the cl ...
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
Prnewswire· 2024-04-08 10:00
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on the NurOwn® program tomorrow, April 9, at 8:00 AM Eastern Time. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, Co-Chief Executive Officer, Stacy Lindborg, PhD an ...
Brainstorm Cell Therapeutics(BCLI) - 2023 Q4 - Annual Report
2024-04-01 13:16
Table of Contents IdentificationNo.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact Name of Registrant as specified in its charter) Delaw ...
Brainstorm Cell Therapeutics(BCLI) - 2023 Q4 - Annual Results
2024-04-01 12:15
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update. "Brainstorm's priority for 2024 i ...
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
Prnewswire· 2024-04-01 12:05
Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update. "Brainstorm's priority for 2024 is to move forward with a confirmatory Phase 3b trial for NurOwn that will potentially support a new Biologics Licen ...
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Prnewswire· 2024-02-23 11:00
NEW YORK, Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS). The submission follows an in-person meeting that BrainStorm held with the FDA in December 2023. The inter ...
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
Prnewswire· 2024-02-13 11:30
NEW YORK, Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzerland. Presentation DetailsPresentation Date: Wednesday, 28th FebruaryTime: 13:40h CETLocation: Panorama Room (Track C), Hilton Zurich Airport Hotel Dr. Stacy Lindborg, Co-C ...
Brainstorm Cell Therapeutics(BCLI) - 2023 Q3 - Earnings Call Transcript
2023-11-14 17:20
Start Time: 08:30 January 1, 0000 8:58 AM ET BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis - Interim CFO Michael Wood - LifeSci Advisors Conference Call Participants David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only ...
Brainstorm Cell Therapeutics(BCLI) - 2023 Q3 - Quarterly Report
2023-11-13 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specifie ...